Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
ORIGINAL ARTICLE

C-Reactive protein and SOFA scale: A simple score as early predictor of critical care requirement in patients with COVID-19 pneumonia in Spain

L.M. Vaquero-Roncero a,⁎, E. Sánchez-Barrado a,⁎, D. Escobar-Macias a, P. Arribas-Pérez a, R. González de Castro b, J.R. González-Porras c, M.V. Sánchez-Hernández a, COVID Working Group

a Departamento de Anestesiología y Reanimación, Hospital Universitario de Salamanca-IBSAL, Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain
b Departamento de Anestesiología y Reanimación, Hospital Universitario de León, Universidad de León, León, Spain
c Departamento de Hematología, Hospital Universitario de Salamanca-IBSAL, Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain

Received 16 August 2020; accepted 20 November 2020
Available online 4 November 2021

KEYWORDS
COVID-19 pneumonia; Critical care; C-reactive protein; Sequential organ failure assessment - SOFA

Abstract
Objective: To identify potential markers at admission predicting the need for critical care in patients with COVID-19 pneumonia.

Material and methods: An approved, observational, retrospective study was conducted between March 15 to April 15, 2020. 150 adult patients aged less than 75 with Charlson comorbidity index ≤6 diagnosed with COVID-19 pneumonia were included. Seventy-five patients were randomly selected from those admitted to the critical care units (critical care group [CG]) and seventy-five hospitalized patients who did not require critical care (non-critical care group [nCG]) represent the control group. One additional cohort of hospitalized patients with COVID-19 were used to validate the score.

Measurements and main results: Multivariable regression showed increasing odds of in-hospital critical care associated with increased C-reactive protein (CRP) (odds ratio 1.052 [1.009-1.101]; P = 0.0043) and higher Sequential Organ Failure Assessment (SOFA) score (1.968 [1.389-2.590]; P < 0.0001), both at the time of hospital admission. The AUC-ROC for the combined model was 0.83 (0.76-0.90) (vs AUC-ROC SOFA P < 0.05). The AUC-ROC for the validation cohort was 0.89 (0.82-0.95) (P > 0.05 vs AUC-ROC development).

⁎ Please cite this article as: Vaquero-Roncero LM, Sánchez-Barrado E, Escobar-Macias D, Arribas-Pérez P, González de Castro R, González-Porras JR, et al. Proteína C reactiva y escala SOFA: una simple escala como factor predictivo temprano de la necesidad de cuidados críticos en los pacientes con neumonía causada por COVID-19 en España. Rev Esp Anestesiol Reanim. 2021;68:513-522.

⁎⁎ Corresponding author.
E-mail address: mesanchezba@saludcastillayleon.es (E. Sánchez-Barrado).
♦ The members of the COVID Working Group, Hospital Universitario de Salamanca-IBSAL, are presented in Appendix A.
PALABRAS CLAVE
Neumonía por COVID-19; Cuidados críticos; Proteína C reactiva; SOFA - evaluación de fallo orgánico secuencial

Proteína C reactiva y escala SOFA: una simple escala como factor predictivo temprano de la necesidad de cuidados críticos en los pacientes con neumonía causada por COVID-19 en España

Resumen
Objetivo: Identificar marcadores potenciales durante el ingreso que predigan la necesidad de cuidados críticos en pacientes con neumonía causada por COVID-19.

Material y métodos: Estudio autorizado, observacional y retrospectivo realizado entre el 15 de marzo y el 15 de abril de 2020; incluyó a 150 pacientes adultos menores de 75 años con índice de comorbilidad de Charlson ≤ 6 diagnosticados de neumonía por COVID-19. Se seleccionaron aleatoriamente 75 pacientes de entre los ingresados en las unidades de cuidados críticos (grupo de cuidados críticos [GC]) y 75 pacientes hospitalizados que no requirieron cuidados críticos (grupo de cuidados no críticos [GNC]) que representaron el grupo control. Se utilizó una cohorte adicional de pacientes hospitalizados con COVID-19 para validar la escala.

Medidas y resultados principales: La regresión multivariante reflejó unos incrementos de los odds ratio de cuidados críticos hospitalarios asociados al incremento de proteína C reactiva (PCR) (odds ratio: 1,052 [1,009–1,101]; p = 0,0043) y puntuaciones en Sequential Organ Failure Assessment (SOFA) más altas (1,968 [1,389–2,590]; p = 0,0001) en el momento del ingreso hospitalario. El valor de la curva AUC-ROC para el modelo combinado fue de 0,83 (0,76–0,90) (frente a AUC-ROC SOFA p < 0,05). El valor de AUC-ROC para la cohorte de validación fue de 0,89 (0,82–0,95) (p < 0,05 frente a AUC-ROC de la cohorte desarrollada).

Conclusión: Los pacientes de COVID-19 que presentan al ingreso una puntuación SOFA ≥ 2 combinada con PCR > 9,1 mg/mL podrían ser de alto riesgo a la hora de requerir cuidados críticos. © 2021 Sociedad Española de Anestesiología, Reanimación y Terapéutica del Dolor. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Introduction

A new atypical pneumonia appeared in December 2019 that was later found to be caused by a new coronavirus (SARS-CoV-2). By April 2020, the virus had spread to 212 countries worldwide, infecting more than 1,607,467 people and causing more than 98,866 deaths. By 9 May, 223,578 cases of infection had been diagnosed in Spain, with 26,478 related deaths. In the early stages of infection patients may experience low grade fever or flu-like symptoms, but this can also be followed by severe respiratory failure. Patients with SARS-CoV-2 infection have high rates of hospitalization and admission to the intensive care unit (ICU). A wide range of parameters have been associated with morbidity and mortality, ranging from sex to increased plasma D dimer levels, which may suggest endothelial activation. Many reports have also described an association between serious clinical deterioration and cytokine storm, characterized by the release of IL-6 and IL-1 type cytokines, and also by traditional inflammatory markers, such as C-reactive protein (CRP) and ferritin. Others suggest that severity can be predicted by different serum inflammatory profiles.

Some patients with SARS-CoV-2 infection may require critical care, and this then becomes one of the main problems faced by healthcare systems during such pandemics. It is still unclear what comorbidities, laboratory test results, or severity features are capable of predicting the potential need for these resources that lead to the collapse of the healthcare system. Good triage criteria and correctly identifying the profiles of high-risk patients could be the cornerstones of individualized management.

In this context, we decided to evaluate our series of COVID-19 patients in order to identify markers observed at admission that could predict the need for critical care.

Material and method

Patient selection

We conducted a retrospective study collecting data from 150 patients diagnosed with COVID-19 pneumonia. All had a confirmed diagnosis of SARS-CoV-2. Seventy-five patients were randomly selected from among those admitted to the critical care units of the Salamanca University Hospital (critical
care (CC)) between 15 March and 15 April 2020. The results of an earlier pilot study in 10 patients showed that patients admitted to the critical care unit were aged under 75 years and had a Charlson comorbidity index 14 of under 6. Therefore, we selected 75 patients admitted to the same hospital during the same period of time who did not require critical care, aged under 75 years and with a Charlson comorbidity index equal to or less than 6 (non-critical group [nCC]) as a control group. Parameters from the nCC were compared with those from the CC.

Exclusion criteria were patients younger than 18 or older than 76, patients with a Charlson comorbidity index greater than 6, and patients in whom essential laboratory results were missing.

ICU admission criteria were: severe refractory respiratory failure secondary to COVID-19 pneumonia, with or without respiratory distress 15, and the need for intubation and mechanical ventilation. Patients were only admitted to the ICU after weighing up the benefits of admission against their underlying comorbidities and frailty.

The study was approved by the Research Ethics Committee of the Hospital Clínico de Salamanca (PI 2020 05 487). The Ethics Committee waived the requirement for informed consent.

Data collection

All study data were collected from the medical records of patients in each group, and included clinical and anthropometric variables and laboratory results on arrival at the hospital emergency unit, prior to admission. We recorded patient-reported symptoms, onset of symptoms, date of hospital admission, date of admission to the critical care unit, and the treatment received. The Sequential Organ Failure Assessment (SOFA) score on arrival at the hospital was calculated to evaluate the patient’s severity 16. All data were reviewed by 2 physicians (PAP and ESB), and discrepancies were resolved by a third investigator (UMVR).

CRP and ferritin were chosen as biomarkers of the activation of different inflammatory pathways that could be associated with worsening clinical status 10,11. Four inflammatory profiles were created on the basis of blood test results.

Laboratory procedures

All patients underwent a SARS-CoV-2 rRT-PCR (real-time reverse transcriptase polymerase chain reaction) diagnostic test on admission using a nasopharyngeal swab. Blood tests included complete blood count, coagulation profile, serum biochemical tests (including kidney and liver function, creatine kinase, lactate dehydrogenase, and electrolytes), CRP, interleukin-6 (IL-6), serum ferritin, and procalcitonin. Chest X-rays and computed tomography (CT) scans were performed on all patients if required during their stay.

Definitions

Fever was defined as an axillary temperature of at least 38°C. COVID-19 pneumonia was described as respiratory symptoms (fever, dry cough, dyspnoea, etc.) plus infiltrates on the chest image 23. Acute respiratory distress syndrome (ARDS) was defined according to the internal WHO guidelines for the new coronavirus 24. Hypoxaemia was defined as a partial pressure of oxygen (PaO2)/inspired fraction of oxygen (FiO2) ratio of less than 300 mmHg, or an SpO2/FiO2 ratio of less than 220 6,8,19. Severe hypoxaemia was defined as PaO2/FiO2 less than 150 mmHg. Severe refractory respiratory failure was defined as failure (increased work of breathing or hypoxaemia) of standard oxygen therapy even after administration of O2 through a non-rebreather face mask (flow rates 10-15 l/min and FiO2 of 0.60-0.95) 19.

Statistical analysis

Data were summarised using descriptive statistics. Missing data were not imputed. Continuous variables were tested for normality using the Kolmogorov-Smirnov test. Quantitative variables are expressed as mean and standard deviation or median and interquartile range (IQR: 25-75), and qualitative variable are expressed as percentages and whole numbers. Quantitative variables were compared using non-parametric tests when the distribution was not normal (Mann-Whitney U test) and parametric when it was normal (Student’s t test). Qualitative variables were compared using the χ² or Fisher’s exact tests.

We calculated the area under the curve (AUC-ROC) of the biomarkers with a p of <0.05 between the two groups in the univariate analysis. Of these, we selected only the 4 parameters with the best AUC in order to include the fewest possible number of covariates for the sample size 21. The parameters chosen were used as covariates in a multivariate model to predict the primary outcome. We excluded variables from the multivariate analysis when the differences between groups were not significant, when the number of events was too small to calculate the odds ratios, and when the variable was co-linear with another variable.

To differentiate the groups, we also calculated the cut-off points for the selected variables by calculating their sensitivity and specificity and determining the best Youden index. We then used a forward stepwise approach (logistic regression) to create a model for the selected biomarkers. Only those with a p-value < 0.05 were included in the model, and those with a p value < 0.10 remained in the model, which was developed using simulated replicated data sets, calculating a mean difference in the AUC-ROC between these models and the best biomarkers, with a 95% CI. The DeLong test was used for this purpose. The Hosmer-Lemeshow multiple regression test was used to calibrate the model. To validate the generalizability of the critical risk scale we used data from a hospital (Hospital Universitario de León) that were not included in the development cohort. The 97 patients in this validation cohort had to fulfil the same inclusion criteria as the patients in the development cohort.

Finally, we obtained the best Youden index cut-off points (CPm) for ferritin and CRP from the ROC curves of these variables by calculating the sensitivity and specificity of these points. We used these data to define 4 inflammatory profiles based on lab results: profile 1 (if CRP >CPm and ferritin >CPm), profile 2 (if CRP >CPm and ferritin <CPm), profile 3 (if CRP <CPm and ferritin <CPm), and profile 4 (if...
CRP < CPM and ferritin < CPM), which were then studied in the two groups. The level of significance was established at p < 0.05.

Statistical analysis was performed on SPSS 21® and Stata 15®.

Results

Between 15 March and 15 April, 150 patients were included in this study: 75 patients who required admission to the ICU and formed the group of critical patients (CC) and 75 patients who did not, and were included in the control group (nCC). All CC patients were intubated and connected to mechanical ventilation. Four patients were excluded from this group due to missing data, so the final sample consisted of 146 patients.

The baseline characteristics and reasons for admission to the ICU are shown in Table 1. Mean age was 66 years (IQR: 57.75–71); 68% of all patients were male (60% in the non-critical group [nCC] vs 76% in the CC group (p < 0.05)). The most common underlying comorbidities were high blood pressure (62 [42.5%]), followed by obesity (46 [31.5%]), diabetes (31 [21.1%]), and heart disease (27 [18.5%]). Our study groups were evenly matched in terms of comorbidities.

Regarding symptoms and signs at the time of hospital admission, fever (119 [85%] patients), cough (86 [59%]) and dyspnoea (59 [40.4%]) were the most commonly reported. There were no significant differences between groups in terms of symptoms.

The mean time from onset of symptoms to hospital admission was 7 days (3–9) in both critical and non-critical patients. The time from disease onset to start of antiviral treatment was 8 days (7–11) in both groups. In the CC group, the mean time from onset of symptoms to admission to the ICU was 9 (7–14) days.

The in-hospital mortality rate was 27.4% in both groups, being significantly higher in the CC (40.8%) compared to the nCC (14.7%) group.

The different treatments administered to patients during their hospitalization are shown in Table 1. Although we observed a trend towards more hydroxychloroquine and azithromycin administration in the CC group (p = 0.05), more significant differences were observed in terms of treatment with high-dose heparin, IL-6 receptor inhibitors and corticosteroids, which were administered in 43%, 69% and 77.1% of patients in the CC group compared to 13.3% (p = 0.0000), 50.7% (p = 0.024) and 40% (p = 0.000) patients in the nCC group, respectively.

Table 2 shows the results of the haemogram, coagulation and biochemical tests performed at the time of hospital admission, including pro-inflammatory markers. In the blood count, neutropaenia and lymphycytopena was more frequently observed in the group of patients who required admission to critical care units. Regarding the biochemical tests, higher baseline levels of creatinine, creatine kinase and lactate dehydrogenase were found in the CC group. Patients who required admission to the ICU also had higher baseline levels of fibrinogen, IL-6, CRP, procalcitonin, and ferritin as pro-inflammatory markers. Finally, the SaO₂/FiO₂ ratio was significantly lower in the CC vs the nCC group. It is interesting to note that patients requiring admission to the ICU presented a considerably higher SOFA score on admission (Table 1). The SOFA score was calculated from 6 different organ system scores, in both groups, particularly in the CC group, the most important scores were obtained from the respiratory item (Tables 1 and 3).

Table 4 shows the AUCs for the parameters with significant differences between the nCC and CC groups and the cut-off points of the parameters that maintained their statistical significance in the logistic regression analysis. These variables were SOFA scale ≥ 7 (70% sensitivity and 76% specificity) and CRP ≥ 9.1 (75% sensitivity and 53% specificity). We also observed that the combined SOFA score and CRP level gave a sensitivity and specificity of 77%, which was significantly higher than the ROC curves for the SOFA score as an isolated variable. The AUC observed here (0.8) suggests that the SOFA score and CRP taken together at the time of hospital admission has a high predictive value.

In our multivariate logistic regression model, a high SOFA score gave an odds ratio of 1,968 for the need for admission to the ICU, and a high CRP value during admission was associated with an odds ratio of 1,052 for the need for ICU admission (Table 5). The presence of high levels of procalcitonin was also associated with an odds ratio of 1.152 for the need for critical care, although it was finally eliminated due to low specificity in the AUC.

The validation cohort included 97 patients with a mean age of 65 years (57–70), of which 71 (73%) were male and 96 (96%) had a Charlson index ≤ 4. The SOFA variables collected for the validation cohort are shown in Table 3. The accuracy of the SOFA score was similar to the validation and development cohorts, with an AUC of 0.89 in the validation cohort (95% CI: 0.82–0.95), a sensitivity of 86%, and a specificity of 72% (p = 0.236 compared to the development cohort).

Table 6 shows the distribution of patients in the nCC and CC groups according to their inflammatory profiles on arrival at the hospital. It is interesting to note that 67.7% of patients with inflammatory profile 1 (CRP ≥ 9.1 mg/dl and ferritin ≥ 969 ng/mL) during admission required critical care, while only 16.1% of those admitted with inflammatory profile 4 (CRP < 9.1 mg/dl and ferritin < 969 ng/mL) required critical care.

Discussion

We developed and validated a clinical risk scale to predict the progression of critical illness among patients hospitalized for COVID-19. The model performed well, showing a precision of 0.8 based on the AUC of both the development and validation cohorts.

The results of this retrospective study show that the presence of CRP levels ≥ 9.1 mg/dl and a SOFA score ≥ 2 in COVID-19+ patients at the time of hospital admission are independent predictors, with a sensitivity and specificity of 77%, of the need for admission to the ICU. This is the first time the combination of both these markers has been used to predict admission to intensive care in COVID-19 patients.

The association of the SOFA score with severity in COVID-19 patients has already been reported in other studies6,10. However, the score of 2 observed in our series gave an acceptable AUC of 0.78 (0.70–0.86), which is in fact the cut-
|                                | Total (n = 146) | Non-critical (nCC) (n = 75) | Critical (CC) (n = 71) | p     |
|--------------------------------|----------------|-----------------------------|------------------------|-------|
| **Mean Age (±: standard deviation)** | 66.00 (57.75–71) | 61.89 (55.25–70)            | 65.11 (60–72)          | 0.162 |
| **Men, n (%)**                 | 99 (67.8)      | 45 (60)                     | 54 (76)                | 0.038 |
| **Charlson index ≤ 4, n (%)**  | 141 (96.6)     | 74 (99)                     | 66 (93)                | 0.105 |
| **Underlying comorbidity, n (%)** |               |                             |                        |       |
| High blood pressure            | 62 (42.5)      | 30 (40)                     | 32 (45)                | 0.223 |
| ACE/ARB inhibitor therapy      | 48 (32.9)      | 21 (28)                     | 27 (38)                | 0.536 |
| Obesity                        | 46 (31.5)      | 22 (29.3)                   | 24 (33.8)              | 0.197 |
| Diabetes                       | 31 (21.2)      | 14 (18.7)                   | 17 (23.9)              | 0.436 |
| History of thrombotic disease  | 9 (6.1)        | 5 (6.7)                     | 4 (5.6)                | 0.346 |
| Heart disease                  | 27 (18.5)      | 15 (20)                     | 12 (16.9)              | 0.674 |
| Immunosuppression              | 13 (8.9)       | 7 (9.3)                     | 6 (8.5)                | 0.852 |
| Kidney failure                 | 11 (7.5)       | 5 (6.7)                     | 6 (8.5)                | 0.683 |
| Smoking                        | 10 (6.8)       | 4 (5.3)                     | 6 (8.5)                | 0.525 |
| COPD                           | 10 (6.8)       | 5 (6.7)                     | 5 (7)                  | 0.928 |
| Asthma                         | 8 (5.5)        | 5 (6.7)                     | 3 (4.3)                | 0.060 |
| OSA                            | 7 (4.8)        | 1 (1.3)                     | 6 (8.5)                | 0.720 |
| Active cancer                  | 3 (2.1)        | 2 (2.7)                     | 1 (1.4)                | 1.000 |
| Others                         | 13 (8.9)       | 7 (9.3)                     | 6 (8.5)                | 0.861 |
| **SOFA, median (IQR)**         | 2 (2–4)        | 1 (0–2)                     | 3 (1–4)                | 0.000 |
| Respiratory SOFA               | 1 (0–3)        | 1 (0–2)                     | 2 (0–3)                | 0.000 |
| Renal SOFA                     | 0 (0–1)        | 0 (0–0)                     | 0 (0–1)                | 0.123 |
| Coagulatory SOFA               | 0 (0–1)        | 0 (0–1)                     | 0 (0–1)                | 0.122 |
| Cardiovascular SOFA            | 0 (0–0)        | 0 (0–0)                     | 0 (0–1)                | 0.345 |
| Liver SOFA                     | 0 (0–0)        | 0 (0–0)                     | 0 (0–0)                | 0.053 |
| Neurological SOFA              | 0 (0–0)        | 0 (0–0)                     | 0 (0–0)                | 0.432 |
| **Non-survivors, n (%)**       | 40 (27.4)      | 11 (14.7)                   | 29 (40.8)              | 0.001 |
| **Signs and symptoms during admission, n (%)** | | | | |
| Fever                          | 119 (85.1)     | 59 (79.7)                   | 60 (84.5)              | 0.364 |
| Cough                          | 86 (58.9)      | 39 (52)                     | 47 (66.2)              | 0.081 |
| Dyspnoea                       | 59 (40.4)      | 31 (41.9)                   | 28 (39.4)              | 0.815 |
| Muscle pain                    | 22 (15.1)      | 11 (14.7)                   | 11 (15.5)              | 0.889 |
| Diarrhoea                      | 19 (13.1)      | 9 (12.0)                    | 10 (14.1)              | 0.708 |
| Asthenia                       | 11 (7.53)      | 9 (12.2)                    | 2 (2.8)                | 0.051 |
| Neurological symptoms          | 8 (5.47)       | 5 (6.7)                     | 3 (4.2)                | 0.314 |
| Sore throat                    | 3 (2.05)       | 1 (1.40)                    | 2 (2.8)                | 1.000 |
| Syncope                        | 3 (2.05)       | 1 (1.40)                    | 2 (2.8)                | 1.000 |
| **Times, median (IQR)**        |                |                             |                        |       |
| Time from disease onset to hospitalization (days) | 7 (3–9) | 7 (3–10) | 6 (3–9) | 0.890 |
| Time from disease onset to start of antiviral therapy (days) | 8 (7–11) | 7 (3–10) | 7 (5–10) | 0.412 |
| Time from disease onset to start of hydroxychloroquine therapy (days) | 7 (4–10) | 7 (3–10) | 7 (4–10) | 0.479 |
| Time from disease onset to start of interleukin-6 receptor blocker therapy (days) | 8 (7–11) | 9 (7–11) | 8 (6–10) | 0.148 |
| Time from disease onset to intensive care admission (days) | NA | NA | 9 (7–14) | NA |
| Time from hospital admission to intensive care admission (days) | NA | NA | 3 (1–5) | NA |
| **Therapy during hospitalization** |                |                             |                        |       |
| No heparin, n (%)             | 11 (7.53)      | 11 (14.6)                   | 0                       | NA    |
| Low-dose heparin, n (%)       | 111 (76.6)     | 54 (72.0)                   | 57 (81.4)              | 0.181 |
| High-dose heparin, n (%)      | 40 (28)        | 10 (13.3)                   | 30 (43)                | 0.000 |
|                               |                |                             | 3 (4.22)               | 0.639 |
Table 1 (Continued)

| Parameter                                      | Total (n = 146) | Non-critical (nCC) (n = 75) | Critical (CC) (n = 71) | p     |
|------------------------------------------------|----------------|-----------------------------|------------------------|-------|
| Azithromycin, n %                              | 120 (82.2)     | 57 (76.0)                   | 63 (88.7)              | 0.054 |
| Interferon, n %                                | 12 (8.2)       | 5 (6.7)                     | 7 (9.9)                | 0.614 |
| Hydroxychloroquine, n %                        | 141 (96.6)     | 70 (93.4)                   | 71 (100)               | 0.059 |
| Lopinavir/ritonavir, %                         | 137 (93.8)     | 68 (90.6)                   | 69 (97.2)              | 0.102 |
| Interleukin-6 receptor blockers, n %           | 87 (48.6)      | 38 (50.7)                   | 49 (69.01)             | 0.024 |
| Interleukin-1 receptor blockers, n %           | 3 (2.1)        | 1 (1.3)                     | 2 (2.8)                | NA    |
| Steroids, n %                                  | 84 (59.7)      | 30 (40)                     | 54 (77.1)              | 0.000 |
|                                              |                |                             | 23 (32.4)              | 0.339 |

COPD: chronic obstructive pulmonary disease; NA: not applicable; OSA: obstructive sleep apnoea; SOFA: sequential organ failure assessment.

a Treatment prior to transfer to the ICU.

Table 2  Laboratory parameters of COVID-19 patients during hospital admission according to ultimate destination.

| Parameter                                      | Total (n = 146) | Non-critical (nCC) (n = 75) | Critical (CC) (n = 71) | p     |
|------------------------------------------------|----------------|-----------------------------|------------------------|-------|
| Creatinine (mg/dl), median (IQR)               | 1.03 (0.81–1.22) | 0.98 (0.72–1.18)           | 1.12 (0.92–1.31)       | 0.015 |
| Bilirubin (mg/dl), median (IQR)                | 0.56 (0.39–0.72) | 0.52 (0.34–0.67)           | 0.57 (0.39–0.76)       | 0.105 |
| Creatine kinase (IU/l), median (IQR)           | 108 (56.25–192) | 87 (52.5–168.5)            | 124.5 (56–306.25)      | 0.047 |
| LDH (IU/l), median (IQR)                       | 358 (286–458)   | 299 (239–365)              | 481 (365–615)          | 0.001 |
| Bilirubin (g/dl), median (IQR)                 | 3.8 (3.4–4.05)  | 3.8 (3.4–4.1)              | 3.7 (3.4–4)            | 0.069 |
| TP (%), median (IQR)                           | 86 (78–96)      | 86 (78–97.5)               | 86.0 (76–94.5)         | 0.645 |
| TTnI (S), median (IQR)                         | 33.6 (30.8–36.9)| 33.5 (31.1–36.7)           | 33.7 (30.3–37.2)       | 0.380 |
| INR, median (IQR)                              | 1.10 (1.03–1.19)| 1.1 (1.0–1.2)              | 1.1 (1.0–1.2)          | 0.799 |
| Fibrinogen (mg/dl), median (IQR)               | 619 (482–796)   | 588 (452–744)              | 676 (538–832)          | 0.016 |
| D-dimer (µg/mL), median (IQR)                  | 0.7 (0.4–1.1)   | 0.7 (0.4–1.0)              | 0.7 (0.4–1.3)          | 0.152 |
| Platelets (×10^9/µl), median (IQR)             | 177 (143–227)   | 180 (135–237)              | 173 (148–226)          | 0.906 |
| Neutrophils (×10^9/µl), median (IQR)           | 5.17 (3.62–6.64)| 4.26 (3.14–6.26)           | 6.13 (3.90–9.86)       | 0.007 |
| Lymphocytes (×10^9/µl), median (IQR)           | 0.795 (0.65–1.11)| 0.94 (0.71–1.22)           | 0.72 (0.62–1.00)       | 0.009 |
| Haemoglobin (g/dl), median (IQR)               | 14.20 (13–15.4) | 14.15 (13–15.33)           | 14.2 (12.95–15.50)     | 0.596 |
| CRP (mg/dl), median (IQR)                      | 10.6 (5.6–20.26)| 8.03 (4.01–14.9)           | 13.49 (8.91–28.98)     | 0.000 |
| Procalcitonin (ng/mL), median (IQR)            | 0.13 (0.08–0.38)| 0.10 (0.06–0.28)           | 0.25 (0.12–0.47)       | 0.000 |
| IL-6 (pg/mL), median (IQR)                     | 42.2 (22.1–111.65)| 31.05 (9.90–42.35)         | 56.55 (21.88–188)      | 0.001 |
| Ferritin (ng/mL), median (IQR)                 | 1,118 (567–2052)| 927 (398–1398)             | 1,416 (805–2606)       | 0.007 |
| Troponin (pg/mL), median (IQR)                 | 12.85 (10.69–18.05)| 15.53 (10.25–17.23)        | 12.85 (9.29–123.08)    | 0.945 |
| SaO₂/FiO₂, median (IQR)                        | 424 (346–448)   | 433 (419–452)              | 361 (180–428)          | 0.000 |

APTT: activated partial thromboplastin time; CRP: C-reactive protein; LDH: lactate dehydrogenase; IL-6: interleukin-6; IQR: interquartile range; PT: prothrombin time.

Normal range: TP (11–13.5 s); APTT (27–40 s); Fibrinogen (130–400 mg/dl); D-dimer (<0.5 µg/mL); Platelet count (150 × 10^9/ l–400 × 10^9/ l); Neutrophil count (1.2–3.5 × 10^9/ l); Lymphocyte count (1.2–5.0 × 10^9/ l); Haemoglobin (90–110 g/L); CRP (<5 mg/L); Creatinine (0.5–1.5 mg/dL); Bilirubin (0.3–1.5 µmol/L); Albumin (40–50 g/L); MCV (80–100 fl); INR (0.8–1.2); Platelets (150–400 × 10^9/ l); CRP (<5 mg/L); IL-6 (<10 pg/mL); TNF-α (<6 pg/mL). Otherwise, the values are expressed as median (IQR).

In our series, the role of CRP as a predictor of the need for critical care maintained its significance in the univariate analysis, and the cut-off point of 9 mg/dl proved to be the most sensitive and specific factor to discriminate between patients who will require critical care versus those who will not. The role of CRP as a predictive factor was maintained in the multivariate analysis. As CRP is mainly synthesised in response to pro-inflammatory cytokines, particularly IL-6 and to a lesser degree IL-1, and tumour necrosis factor alpha (TNF-α), it should be determined at the time of admission, since it is more accessible than the other proxies of pro-inflammatory cytokine.

off point for distinguishing between septic and non-septic patients. Although this applies to bacterial infections, viral infections can lead to sepsis, and nearly 40% of adults with community-acquired pneumonia due to viral infection develop sepsis.

In our series, the SOFA score was shown to be a predictor of the need for critical care after correcting for the remaining main covariates, such as CRP, procalcitonin, and sex. Tables 1 and 3 show the importance of the respiratory item in the SOFA score at the time of admission, as expected.

Regarding CRP, other authors have reported that high values are related to prognosis and severity in COVID-19.
In our series, a combination of CRP and SOFA yielded an AUC of 0.83 (0.76–0.90). This is excellent for predicting the need for intensive care during admission, and to our knowledge had not been previously reported. It is also plausible on a biological level, since, as in other infectious processes\(^{25}\), the combination of one of the main markers of inflammation (CRP) with a validated organ failure scale (SOFA) can provide a more accurate diagnosis/prognosis in patients with COVID-19.

Another important finding in this study has been that almost 70% of patients admitted with CRP levels of over 9.1 mg/dL and ferritin of over 969 ng/mL required critical care. This suggests that these parameters can also accurately predict prognosis. An inflammatory profile consisting of CRP < 9.1 mg/dL and ferritin < 969 ng/mL would help identify patients that are unlikely to require critical care. In fact, only 16% of patients in our series with this profile required admission to the ICU.

As mentioned previously, CRP is involved in the IL-6 pathway. IL-1 and IL-6 have been shown to trigger acute activation of endothelial cells\(^{24}\) causing high levels of these and other cytokines in critically ill patients\(^ {26}\). Ferritin is also involved in the IL-1 pathway\(^ {10,11}\), therefore, the combination of CRP and ferritin may constitute an inflammatory pattern with prognostic potential.

Procalcitonin has been associated with prognosis in patients with an inflammatory response similar to that found in our series\(^ {27}\). However, its role as a predictor of critical care was not maintained in the multivariate analysis, perhaps due to its poor diagnostic performance in viral infections\(^ {28}\).

Sex has been described in other series as a prognostic factor\(^ {6,9}\) of overall mortality. However, in our study, male sex did not predict an increased risk of requiring critical care. The same was true of time to hospital admission or

---

**Table 3** Laboratory characteristics of patients in the validation cohort, sensitivity and specificity, and cut-off points.

| Parameter          | Total (n = 97) | Non-critical (n = 45) | Critical (n = 52) | Sensitivity (%) | Specificity (%) |
|--------------------|---------------|-----------------------|-------------------|----------------|-----------------|
| CRP (mg/dL) median (IQR) | 10.9 (6.5–29.8) | 7.4 (1.8–11.8) | 16.8 (9.5–25.6) | 77% S; 63% Sp | |
| SOFA, median (IQR) | 3 (2–4) | 2 (1–3) | 4 (3–4) | 86% S; 69% Sp | |
| Respiratory SOFA | 2 (1–3) | 1 (0–2) | 3 (2–3) | | |
| Renal SOFA | 0 (0–0) | 0 (0–0) | 0 (0–0) | | |
| Coagulatory SOFA | 0 (0–0) | 0 (0–0) | 0 (0–1) | | |
| Cardiovascular SOFA | 0 (0–0) | 0 (0–0) | 0 (0–1) | | |
| Liver SOFA | 0 (0–0) | 0 (0–0) | 0 (0–0) | | |
| Neurological SOFA | 0 (0–0) | 0 (0–0) | 0 (0–0) | | |

CRP: C-reactive protein; SOFA: sequential organ failure assessment.

Multiple regression: OR SOFA: 2.46 (1.54–3.95); OR CRP: 1.08 (1.01–1.16).

Hosmer-Lemeshow test: $X^2$ = 4.71; 8 gl; p = 0.785.

---

**Table 4** AUC-ROC and cut-off point, sensitivity and specificity of COVID-19 parameters to predict the likelihood of critical care at the time of admission.

| Parameter          | AUC-ROC | Cut-off point | Sensitivity (%) | Specificity (%) |
|--------------------|---------|---------------|----------------|----------------|
| SOFA               | 0.78 (0.70–0.86) | ≥ 2 | 70 | 76 |
| Procalcitonin      | 0.74 (0.66–0.83) | ≥ 0.1 ng/mL | 88 | 52 |
| CRP                | 0.69 (0.61–0.78) | ≥ 9.1 mg/dL | 75 | 53 |
| Ferritin\(^ a\)    | 0.68 (0.56–0.83) | ≥ 969 ng/mL | 74 | 56 |
| LDH                | 0.67 (0.58–0.76) | NA | | |
| Neutrophils        | 0.64 (0.56–0.73) | NA | | |
| Lymphocytes        | 0.63 (0.54–0.73) | NA | | |
| Glucose            | 0.63 (0.54–0.72) | NA | | |
| Fibrinogen         | 0.63 (0.53–0.72) | NA | | |
| CK                 | 0.62 (0.52–0.71) | NA | | |
| IL-6\(^ a\)        | NA | NA | | |
| Combination (SOFA-CRP) | 0.83 (0.76–0.90) | ≥ 0.43\(^ b\) | 77 | 77 |

CK: creatine kinase; CRP: C-reactive protein; IL-6: interleukin-6; NA: not applicable; SOFA: sequential organ failure assessment.

\(^ a\) Ferritin and IL-6 are excluded from the model due to the low number of subjects.

\(^ b\) Cut-off point for combination SOFA-CRP = 1 + 1/e−2,186 $\times$ 0.68 $\times$ SOFA score $+$ 0.05 $\times$ CRP value.

---

**Table 5** Multiple regression using the 4 covariates of interest.

| Parameter          | B coefficient | OR (95% CI) |
|--------------------|---------------|-------------|
| SOFA               | 0.68          | 1.968 (1.389–2.590) |
| CRP                | 0.05          | 1.052 (1.009–1.101) |
| Procalcitonin      | 0.14          | 1.152 (0.770–1.979) |
| Sex                | −0.21         | 0.806 (0.309–1.993) |
| Constant           | −2.19         | 0.519 (0.282–0.949) |
to start of treatment. Comorbidity derived from underlying diseases upon arrival at the hospital was similar in both groups, except for asthma, which has been identified in other studies\textsuperscript{29}. Regarding treatment, the group of critically ill patients received more than expected amount of high-dose heparin, interleukin receptor inhibitors, and corticosteroids, due to their severity.

Other authors have suggested that LDH, CK, and white blood cells can be prognostic factors\textsuperscript{1,5,7,10}, particularly of viral load (LDH and CK)\textsuperscript{10}. In our case, they were not included in the multivariate analysis because they presented a lower AUC than that required for diagnosis.

Our study has certain limitations due to its retrospective nature, and some laboratory data were missing in some patients. We used a small sample to construct the risk scale and a relatively small sample for validation purposes. Despite this small sample size, the inclusion of randomized adult COVID-19 patients is representative of the number of cases treated in critical care units.

Finally, in general and as expected, the in-hospital mortality rate in patients who required admission to the ICU was more than double that of patients not requiring critical care. The mortality rate reported here is consistent with that published in other series\textsuperscript{1}, and shows that it is crucial to identify this group of patients at the time of admission. As patients with a SOFA score > 2 and high levels of CRP appear more likely to require critical care, additional therapeutic actions could be taken to reduce the need for such care and thus reduce the in-hospital mortality rate. However, further studies and prospective trials are needed to support this finding.

**Conclusion**

COVID-19 patients with a SOFA score ≥ 2 and CRP ≥ 9.1 mg/mL could constitute a population that is most likely to require critical care.

**Funding**

The authors have not received any specific grant from any financial institution in the public, commercial or non-profit sectors.

**Authorship**

LMVR designed the study. Data were collected by ESB, DEM, PAP and RG. Data analysis was performed by LMVR. LMVR and JRG performed the manuscript with input from all authors. MVSH critically reviewed the manuscript for important intellectual content. All authors approved the final version of the study.

**Conflict of interests**

None.

**Acknowledgements**

We would like to thank María-Victoria Mateos from the Department of Haematology for her help in reviewing this document, and also Pedro Luis Sánchez-Fernández from the Department of Cardiology and all the doctors and healthcare personnel involved in the COVID-19 Task Force.

We would also like to thank all the members of the Department of Anaesthesiology and Resuscitation: Jordana Almeida, Daniel Álvarez, Laura Alonso, Begoña Alonso, Marta Criado, Isabel de Celis, Alberto de Diego, Esther del Barrio, Carlos Espinell, Iolanda Freire, Emilio García, Isabel Garrido, Eugenia González, María Heredia, Felipe Hernández, Janna Herrmanova, Jose Luís Iglesias, Elisa Jausoro, Diego Leoz, Adela López, Rocío López, Pamela López, Virgilio Martín, Laura Nieto, M. Jesús Pascual, Diego Pérez, Isabel Pingarrón, Rosa Prieto, J.M. Rodríguez, Mercedes Rojo, Cruz Ruano, Daniel Salgado, Lucio San Norberto, Pilar Sánchez, Manuel J. Sánchez, Eduardo Sánchez, Francisco J. Sánchez, David Sánchez, Valentín Santana, Ignacio Trejo, Joaquin Valduncan, Ana Vara, M. José Villorra, Gema Yusta.

Finally, our thanks go to all the COVID-19 patients admitted to the Salamanca University Hospital, as well as their families.

**Appendix A. COVID Task Force, Salamanca University Hospital-IBSAL**

Jesús F. Bermejo-Martín, MD, PhD. Biomedical research group on sepsis (BioSepsis), IBSAL. Faculty of Medicine, University of Salamanca.

Cristina Doncel. Biomedical research group on sepsis (BioSepsis), IBSAL. Faculty of Medicine, University of Salamanca.

José María Bastida, MD, PhD. Haematology Department, Salamanca University Hospital-IBSAL. Faculty of Medicine, University of Salamanca.

Azucena Hernández-Valero, MD. Department of Anaesthesiology and Resuscitation, Salamanca University Hospital-IBSAL. Faculty of Medicine, University of Salamanca.

Table 6  Inflammatory profile in COVID-19 patients during admission, according to their ultimate destination.

| Profile, n (%) | Total (n = 65) | Non-critical (n = 34) | Critical (n = 31) | p |
|---------------|---------------|----------------------|------------------|---|
| Profile 1, n (%) (CRP ≥ 9.1 mg/dl and ferritin ≥ 969 ng/mL) | 30 (46.2) | 9 (26.5) | 21 (67.7) | 0.007 |
| Profile 2, n (%) (CRP ≥ 9.1 mg/dl and ferritin < 969 ng/mL) | 9 (13.8) | 6 (17.6) | 3 (9.7) | 1.000 |
| Profile 3, n (%) (CRP < 9.1 mg/dl and ferritin ≥ 969 ng/mL) | 8 (12.3) | 6 (17.6) | 2 (6.5) | 0.563 |
| Profile 4, n (%) (CRP < 9.1 mg/dl and ferritin < 969 ng/mL) | 18 (27.7) | 13 (38.2) | 5 (16.1) | 0.016 |

Calculated in patients with ferritin and CRP lab results.
Reference

1. WHO main website. Available from: https://www.who.int. [Accessed May 2020].
2. Actualización n°100 (09.05.2020). Enfermedad por el coronavirus. Centros de Coordinación de Alertas y Emergencias Sanitarias. Ministerio de Sanidad. Gobierno de España.
3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
4. Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. JAMA. 2020;233:1545–6.
5. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.
6. Yao Q, Wang P, Wang X, Qie G, Meng M, Tong X, et al. Retrospective study of risk factors for severe SARS-CoV-2 infections in hospitalized adult patients. Pol Arch Intern Med. 2020, http://dx.doi.org/10.20452/pamw.15312.
7. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368, http://dx.doi.org/10.1136/bmj.m1091.
8. Deng G, Yin M, Chen X, Zeng F. Clinical determinants for fatality of 44,672 patients with COVID-19. Crit Care. 2020;24:179.
9. Meng Y, Wu P, Lu W, Liu K, Ma K, Huang L, et al. Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan, China: a retrospective study of 168 severe patients. PLoS Pathog. 2020;16:e1008520.
10. Hurlimann J, Thorbecke JH, Hochwald GM. The liver as the site of C reactive protein formation. J Exp Med. 1966;123:365–78.
11. Emmenegger U, Reimers A, Frey U. Reactive macrophage activation syndrome: a simple screening strategy and its potential in early treatment initiation. Swiss Med Wkly. 2002;132:230–6.
12. Rascado Sedes P, Ballesteros Sanz MA, Bodi Saera MA, Carrasco Rodriguez-Rey LF, Castellanos Ortega A, Catalán González M, et al. Plan de contingencia para los servicios de medicina intensiva frente a la pandemia COVID-19. Med Intensiva. 2020, http://dx.doi.org/10.1016/j.medin.2020.03.006.
13. Matheny Antommaria AH, Gibb TS, McGuire AL, for a Task Force of the Association of Bioethics Program Directors. Ventilator triage policies during the COVID-19 pandemic at U.S. hospitals associated with members of the association of bioethics program directors. Ann Intern Med. 2020;173:188–94.
14. Charlton ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.
15. WHO. Novel coronavirus – China. Jan 12, 2020. Available from: http://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/. [Accessed 20 April 2020].
16. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801–10.
17. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020. http://dx.doi.org/10.1016/S0140-6736(20)30566-3.
18. Pandharipande PP, Shintani AK, Hagerman HE, St. Jacques PJ, Rice TW, Sanders NW, et al. Derivation and validation of SpO2/FIO2 ratio to impute for PaO2/ FIO2 ratio in the respiratory component of the Sequential Organ Failure Assessment (SOFA) Score. Crit Care Med. 2009;37:1317–21.
19. Rice TW, Wheeler AP, Bernard GR, Hayden DL, Schoenfeld DA, Ware LB, et al. Comparison of the SpO2/FIO2 ratio and the PaO2/FIO2 ratio in patients with acute lung injury or ARDS. Chest. 2007;132:410–7.
20. Narendra DK, Hess DR, Sessler CN, Belete HM, Guntupalli KK, Khusid F, et al. Update in management of severe hypoxemic respiratory failure. Chest. 2017;152:867–79.
21. Sánchez-Cantalejo ES. Regresión Logística en Salud Pública. Granada, España: Escuela Andaluza de Salud Pública; 2000.
22. Zhou F, Wang Y, Liu Y. Disease severity and clinical outcomes of community-acquired pneumonia caused by non-influenza respiratory viruses in adults: a multicentre prospective registry study from the CAP-China Network. Eur Respir J. 2019;54:1802406.
23. Li H, Xiang X, Ren H, Xu L, Zhao L, Chen K, et al. Serum amiloid is a biomarker to distinguish the severity and prognosis of Coronavirus Disease 2019 (COVID-19). J Infection. 2020;80:646–55.
24. Yang Y, Xie J, Guo F, Longhini F, Gao Z, Huang Y. Risk factors for disease progression in hospitalized patients with COVID-19: a retrospective cohort study. Infect Dis (Lond). 2020. http://dx.doi.org/10.1080/23744235.2020.1759817.
25. Yang Y, Xie J, Guo F, Longhini F, Gao Z, Huang Y, et al. Combination of C-reactive protein, procalcitonin and sepsis-related organ failure score for the diagnosis of sepsis in critical patients. Ann. Intensive Care. 2016;6:51.
26. Levi M, van der Poll T. Coagulation and sepsis. Thromb Res. 2017;149:38–44.
27. Tugrul S, Esen F, Celebi S, Ozcan PE, Akinci O, Cakar N, et al. Reliability of procalcitonin as a severity marker in critically ill patients with inflammatory response. Anaesth Intensive Care. 2002;30:747–54.
28. Ip M, Rainer TH, Lee N, Chan C, Chau SS, Leung W, et al. Value of serum procalcitonin, neopterin, and C-reactive protein in differentiating bacterial from viral etiologies in patients presenting with lower respiratory tract infections. Diagn Microbiol Infect Dis. 2017;9;131.
29. Pennington E. Asthma increases risk of severity of COVID-19. Cleve Clin J Med. 2020, http://dx.doi.org/10.3949/ccjm.87a.ccc002.
30. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. China Life Sci. 2020;63:364–74.